New Dual-Targeting CAR t therapy takes on Hard-to-Treat myeloma

NCT ID NCT07369895

Recruiting now Disease control Sponsor: O&D BioTech Group CO., Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new cell therapy called O&D-001 for people with multiple myeloma that has come back or stopped responding to treatment. The therapy uses a patient's own immune cells, modified to attack two cancer targets (BCMA and GPRC5D). The study will enroll 18 adults and focus on safety and dosing, with some early signs of effectiveness also tracked.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: O&D-001 CAR T cells (a type of immune cell therapy that targets two proteins on cancer cells)
What this could lead to: If it works, this could offer a new treatment option for people with multiple myeloma that has not responded to other therapies.
What could go wrong: This is a very early, small Phase 1 trial with only 18 participants, so it is too soon to know if it will be safe or effective. There are risks of serious side effects from the cell therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.